<DOC>
	<DOCNO>NCT01161173</DOCNO>
	<brief_summary>This observational study evaluate safety efficacy Tarceva ( erlotinib ) routine clinical practice second-line treatment patient recurrent metastatic non-small dell lung cancer ( NSCLC ) . Data collect patient receive 1 course standard systemic chemotherapy , experience disease progression , receiveingTarceva second-line setting . Patients also follow third-line treatment disease progression Tarceva therapy .</brief_summary>
	<brief_title>An Observational Study Tarceva ( Erlotinib ) Routine Daily Clinical Practice Second Line Treatment Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patient â‰¥ 18 year age . Written informed consent . Recurrent metastatic , Stage III IV nonsmall cell lung cancer ( NSCLC ) . Measurable disease ( Response Evaluation Criteria In Solid Tumors ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Prior course standard systemic chemotherapy . Contraindications treatment Tarceva .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>